Presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in necrotizing enterocolitis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Bleeding complications: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in bleeding complications: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Sepsis: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in sepsis: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Mortality (all infants): 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in mortality (all infants): 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
Intraventricular hemorrhage > Grade II: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in intraventricular hemorrhage > Grade II: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Intervention not reported
Treatment 3: topical levofloxacin 0.5% · participants undergoing cataract surgery
1 finding from 1 review
no estimate extracted
16603 participants
Moderate
Mean noise attenuation over 0.5, 1, 2, 3, 4, 6, 8 kHz (dB) Immediate · workers exposed to noise
1 finding from 1 review
Intervention not reported
Eyes within ± 0.5 D of target refraction · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes eyes within ± 0.5 D of target refraction (very low certainty).
1 finding from 1 review
RR 0.69 [0.48, 0.99]
Studies not reported
Very low
Intervention not reported
Failure to achieve peak levels of at least 5 microgram/ml (measured 0.5 to one hour after administration of any dose of gentamicin) · neonates with suspected or proven sepsis
The intervention probably leads to lower failure to achieve peak levels of at least 5 microgram/ml (measured… (moderate certainty).
1 finding from 1 review
Intervention not reported
0.5% CMC vs. sodium hyaluronate · people with dry eye
1 finding from 1 review
Intervention not reported
0.5% CMC vs. 0.3% HPMC · people with dry eye
1 finding from 1 review
Intervention not reported
0.5% CMC vs 1% CMC · people with dry eye
1 finding from 1 review
Intervention not reported
0.5% CMC vs 0.5% CMC + castor oil vs. 1.0% glycerine + castor oil · people with dry eye
1 finding from 1 review